MilliporeSigma and the Broad Institute of MIT and Harvard entered an agreement to offer non-exclusive licenses to CRISPR intellectual property (IP) under their respective control for use in commercial research and product development.   “Together with the Broad Institute, we are simplifying the path to licensing CRISPR technology, which will make it more widely available to the global research and discovery community,” said Udit Batra, CEO, MilliporeSigma. “Through this agree...